Physician profile
Eric Sladek
NPI 1124433297
$3,230.63
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.00 · 2020: $146 · 2021: $396 · 2022: $814 · 2023: $760 · 2024: $541 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $870.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $348.09 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $232.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.86 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.58 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $196.04 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $164.44 | 2022-2023 | Spravato |
| Amgen INC. | $135.69 | 2021-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $117.32 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $115.99 | 2022-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $112.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $78.89 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $57.68 | 2019-2022 | |
| Lilly USA, LLC | $54.83 | 2022-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $45.15 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.27 | 2023-2024 | Watchman Flx, Watchman Access System |
| Axsome Therapeutics, INC. | $37.12 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $32.56 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $26.72 | 2025 | Voquezna |
| Inari Medical, INC. | $25.51 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $24.04 | 2025 | |
| Dexcom, INC. | $22.86 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $19.40 | 2021 | |
| Averitas Pharma INC. | $18.73 | 2023 | Qutenza |
| Glaxosmithkline, LLC. | $14.64 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sladek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.